

Stanford



Sumit Shah

Clinical Associate Professor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- Stanford Cancer Center

875 Blake Wilbur Dr Clinic E
Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 736-7379

Bio

BIO

Dr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

CLINICAL FOCUS

- Oncology
- Prostate Cancer
- Kidney Cancer
- Bladder Cancer
- Testicular Cancer/Germ Cell Tumor
- Immunotherapy

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- US Fulbright Scholar, South Korea (2005)

PROFESSIONAL EDUCATION

- Residency: UCSF Dept of Internal Medicine (2013) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA

- Medical Education: Stanford University School of Medicine (2010) CA
- Fellowship, Stanford University Hospital , Oncology/Hematology (2017)
- Residency, University of California, San Francisco (UCSF) , Internal Medicine (2013)
- MPH, Harvard School of Public Health (2010)
- MD, Stanford School of Medicine (2010)
- BSE, Duke University (2004)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC), Recruiting

Teaching

STANFORD ADVISEES

Academic Advising Dean

David Altman, Elizabeth Asonye, Ankit Baghel, Bryce-Allen Bagley, Wills Baird, Elizabeth Beam, Preksha Bhagchandani, Alex Burgess, Christian Calderon, Tim Chai, Michelle Chang, Maggie Chen, Mira Cheng, Suyoung Choi, Samuel Cohen, Shayna Cooperman, Anthony Cort, Greta Cywinska, Areian Eghbali, Sofia Essayan-Perez, Allan Feng, Brandon Foster, Cesar Garcia, Bereket Gebregziabher, Cayo Gonzalez, Jonathan Goodman, Jessica Hampton, Marissa Huang, Zoe Hughes, Edoghogho Ighodaro, Shammah Ike, Kendra Jackson, Candice Kim, Chelsea Li, Michelle Lin, Daniel Liu, Long Sha Liu, Shirley Liu, Mary Lopez Isidro, Sofia Luna, Lucy Ma, Kajal Maran, Payton Marshall, Michael Mayer, Vilina Mehta, Jack Michaud, Paras Minhas, Haley Morin, Priyanka Multani, Kabungo Mulumba, Caroline Murtagh, Michael Nedelman, Sidney Owen, Madison Palmer, Ragini Phansalkar, Srinidhi Polkampally, Nathaniel Porter, Mollie Qian, Santiago Sanchez, Ben Schwartz, Aadit Shah, Mihir Shah, Jason Shen, Benjamin Smith, Jodi So, Elijah Sommer, Akshay Swaminathan, Jason Thomas, Austin Valido, Harsh Wadhwa, Songnan Wang, Christine Xu, Josiah Yarbrough, Christine Yiwen Yeh, Willemijn van Deursen

Publications

PUBLICATIONS

- **The Will to Go On.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Shah, S.
2022: JCO2201188
- **Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.** *Lancet (London, England)*
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y. n., Rubinstein, S. M., Rivera, D. R., Shete, S. n., Hsu, C. Y., Desai, A. n., de Lima Lopes, G. n., Grivas, P. n., Painter, C. A., Peters, et al
2020
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Consolidative Radiotherapy in Metastatic Urothelial Cancer.** *Clinical genitourinary cancer*
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., Srinivas, S.
2017

- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.** *European journal of nuclear medicine and molecular imaging*
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al 2024
- **Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.** *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., Srinivas, S., Fan, A. C., Shah, S., Patel, M. I.
2024; 32 (3): 161
- **COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.** *Translational oncology*
Moey, M. Y., Hennessy, C., French, B., Warner, J. L., Tucker, M. D., Hausrath, D. J., Shah, D. P., DeCara, J. M., Bakouny, Z., Labaki, C., Choueiri, T. K., Dent, S., Akhter, et al
2023; 34: 101709
- **Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes**
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**
Jindal, T., Zhang, L., Jiang, C., Kilari, D., Alhalabi, O., Nizam, A., Basu, A., Bilen, M., Zakharia, Y., Milowsky, M. I., Shah, S., Hoimes, C. J., Davis, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis**
Kommalapati, A., Laliotis, G., Glover, M., Selig, G., Kollipara, R., Mahmood, T., Shah, S., Hoimes, C. J., Stewart, T. F., Sharma, S., Malhotra, M., Pajak, N., Calhoun, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.** *BMC cancer*
Johnson, D. B., Atkins, M. B., Hennessy, C., Wise-Draper, T., Heilman, H., Awosika, J., Bakouny, Z., Labaki, C., Saliby, R. M., Hwang, C., Singh, S. R., Balanchivadze, N., Friese, et al
2023; 23 (1): 265
- **Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.**
Khaki, A., Fan, A. C., Shah, S., Parikh, D., Chien, J., Moore, K., Ruiz, S., Haas, D., Fakhoury, L., Del Toro, N., Baker, P., O'Brien, A., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.**
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A., Basu, A., Barata, P. C., Bilen, M., Shah, S., Zakharia, Y., Milowsky, M. I., Bellmunt, J., Emamekhoo, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).**
Koshkin, V. S., Henderson, N., Kilari, D., Jindal, T., Alhalabi, O., Freeman, D., Basu, A., Barata, P. C., Bilen, M., Zakharia, Y., Emamekhoo, H., Shah, S., Milowsky, et al
LIPPINCOTT WILLIAMS & WILKINS.2023
- **In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.** *European urology*
Molina, G. E., Schwartz, B., Srinivas, S., Shah, S., Zaba, L. C.
2023
- **Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population.** *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B. I., Shah, S. A., DeRouen, M. C., Cheng, I.
2022
- **Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.** *JCO oncology practice*

Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., Rogers, B., Hansen, J., DeNofrio, J., Shah, et al
2022: OP2200128

- **Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.** *JAMA oncology*
Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C. Y., Alimohamed, S. I., Bashir, B., Berg, S., Bilen, M. A., Bowles, D., Castellano, C., Desai, et al
2022
- **Characterization of remote second-opinion oncology patients and associated changes in management.**
Shah, A. P., Shi, S., Shah, S.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18563
- **Post-acute sequelae of SARS-CoV-2 infection in patients with cancer.**
Warner, J., Pinato, D., Mishra, S., Saliby, R., Hwang, C., Gulati, S., Mckay, R. R., Labaki, C., Griffiths, E. A., Jani, C., Yu, P., Portuguese, A., Puc, et al
LIPPINCOTT WILLIAMS & WILKINS.2022: E18746
- **COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).**
Beeghly-Fadiel, A., Prescott, L. S., Ruiz-Garcia, E., Hwang, C., Heilman, H., Mckay, R. R., Saliby, R., Lau, S., Nagaraj, G., Puc, M., Zsiros, E., Shah, S., Jani, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.** *Blood cancer discovery*
Rubinstein, S. M., Bhutani, D., Lynch, R. C., Hsu, C., Shyr, Y., Advani, S., Mesa, R. A., Mishra, S., Mundt, D. P., Shah, D. P., Sica, R. A., Stockerl-Goldstein, K. E., Stratton, et al
2022
- **Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.** *Open forum infectious diseases*
Satyanarayana, G., Enriquez, K. T., Sun, T., Klein, E. J., Abidi, M., Advani, S. M., Awosika, J., Bakouny, Z., Bashir, B., Berg, S., Bernardes, M., Egan, P. C., Elkrief, et al
2022; 9 (3): ofac037
- **Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.**
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., Kao, C., Shah, S., Srinivas, S., Fan, A. C., Khaki, A.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.** *JAMA network open*
Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S. R., Venepalli, N. K., Bakouny, et al
1800; 5 (1): e2142046
- **Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.** *Cancer*
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., Su, C. T., Khaki, A. R., Osterman, C. K., Glover, M. J., Chiang, R., Makrakis, D., Talukder, et al
2021
- **Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer**
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M., Alves, N., Rogers, B., Neal, J. W., Fan, A. C., Parikh, D., Patel, M. I., Shah, S., Srinivas, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.** *Journal of patient-reported outcomes*
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., Velazquez, B., Chu, G., Bruzzone, B., Cabot, A., Fisher, G. A., Srinivas, S., Fan, et al
2021; 5 (1): 91
- **Patterns in cancer management changes for patients with COVID-19 in northern California.**
Glover, M., Wu, J., Kwon, D. H., Zhang, S., Henry, S., Wood, D., Rubin, D., Borno, H., Small, E., Schapira, L., Koshkin, V. S., Shah, S.
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Reply to R. Kebudi et al.** *JCO oncology practice*

Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., Koshkin, V., Schapira, L., Shah, S. A.

2021; OP2100105

- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buuyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
2021
- **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137–39
- **Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.** *Urologic oncology*
Bhambhvani, H. P., Greenberg, D. R., Kasman, A. M., DeRouen, M. C., Cheng, I., Eisenberg, M. L., Shah, S. A.
2021
- **Remote Oncology Care: Review of Current Technology and Future Directions.** *Cureus*
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.
2020; 12 (8): e10156
- **Remote Oncology Care: Review of Current Technology and Future Directions** *CUREUS*
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., Hendifar, A. E.
2020; 12 (8)
- **Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.** *Cancer discovery*
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C., Rubinstein, S. M., Lee, B. J., Choueiri, T. K., de Lima Lopes, G., Grivas, P., Painter, C. A., Rini, et al
2020
- **Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.** *Urologic oncology*
Bhambhvani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., Liao, J., Shah, S., Srinivas, S., Skinner, E. C., Shah, J. B.
2020
- **Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)**
Rubinstein, S., Grivas, P., Choueiri, T. K., Kuderer, N., Shah, D., Rivera, D. R., Gupta, S., Bilen, M., Halldanarson, T., Doroshow, D., Wehbe, F., Shah, S., Shyr, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
- **Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions**
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B., Shah, S. A., DeRouen, M. C., Gomez, S. L., Cheng, I.
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California**
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B., Gomez, S. L., Cheng, I.
AMER ASSOC CANCER RESEARCH.2020
- **Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.** *Cancer causes & control : CCC*
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Chung, B. I., Gomez, S. L., Cheng, I.
2020
- **DEVELOPING THE ADVANCED PRACTICE ROLE IN INFUSION TREATMENT AREA**
Shah, D., Kuriakose, C., Healy, D., Shah, S.
ONCOLOGY NURSING SOC.2020
- **Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.** *Journal for immunotherapy of cancer*

Martinez Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., Lam, E., Zakharia, Y., Mckay, R., Shah, S., Mortazavi, A., R Harrison, M., Sideris, et al
2020; 8 (1)

● **Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.** *JCO oncology practice*

Wu, J. T., Kwon, D. H., Glover, M. J., Henry, S. n., Wood, D. n., Rubin, D. L., Koshkin, V. S., Schapira, L. n., Shah, S. A.
2020: OP2000790

● **Feasibility and design of a cloud-based digital platform in patients with advanced cancer.**

Roy, M., Hall, E., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., San Pedro-Salcedo, M., Wakelee, H. A., Neal, J. W., Padda, S., Das, M., Fan, A. C., Srinivas, et al
AMER SOC CLINICAL ONCOLOGY.2019

● **Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).**

Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., Lam, E., Zakharia, Y., Mckay, R. R., Shah, S., Mortazavi, A., Harrison, M., Choueiri, et al
AMER SOC CLINICAL ONCOLOGY.2019

● **Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study** *LANCET ONCOLOGY*

Changa, N., Xie, W., Bilen, M., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., Balakrishnan, A., Bowman, I., Jain, R., Stadler, W., Zakharia, Y., Narayan, V., Beuselinck, et al
2019; 20 (4): 581–90

● **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.** *Journal of the National Comprehensive Cancer Network : JNCCN*

Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., Gomez, S. L., Cheng, I.
2018; 16 (11): 1353–60

● **Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B., Gomez, S. L., Cheng, I.
2018; 16 (11): 1353-1360

● **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**

Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al
ELSEVIER SCIENCE INC.2017: S108–S109

● **Prognostic factors for pancreatic metastases in renal cell cancer.**

Chung, A., Li, S., Shah, S., Fan, A. C., Srinivas, S.
AMER SOC CLINICAL ONCOLOGY.2016

● **In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study** *BLOOD*

Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., Morales, A., Abdulla, F., Xing, L., Navi, D., Tibshirani, R. J., Advani, R. H., Lingala, et al
2012; 119 (2): 355-363